Recombinant Anti-Fibrinogen alpha chain antibody [EPR2918] (ab108616)


  • Product name

    Anti-Fibrinogen alpha chain antibody [EPR2918]
    See all Fibrinogen alpha chain primary antibodies
  • Description

    Rabbit monoclonal [EPR2918] to Fibrinogen alpha chain
  • Host species

  • Specificity

    The immunogen is derived from isoform alpha-E, UniProt accession P02671-1, and the antibody is not expected to detect isoform alpha.
  • Tested applications

    Suitable for: WBmore details
    Unsuitable for: IHC-P or IP
  • Species reactivity

    Reacts with: Human
  • Immunogen

    Synthetic peptide within Human Fibrinogen alpha chain aa 650-800. The exact sequence is proprietary. The immunogen is derived from isoform alpha-E, UniProt accession P02671-1, and the antibody is not expected to detect isoform alpha.
    Database link: P02671-1

  • Positive control

    • WB: Human plasma and fetal liver lysates.
  • General notes

    Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.


    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.

    This product is a recombinant rabbit monoclonal antibody.



Our Abpromise guarantee covers the use of ab108616 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/2000 - 1/10000. Predicted molecular weight: 95 kDa.
  • Application notes
    Is unsuitable for IHC-P or IP.
  • Target

    • Function

      Fibrinogen has a double function: yielding monomers that polymerize into fibrin and acting as a cofactor in platelet aggregation.
    • Tissue specificity

    • Involvement in disease

      Defects in FGA are a cause of congenital afibrinogenemia (CAFBN) [MIM:202400]. This is a rare autosomal recessive disorder characterized by bleeding that varies from mild to severe and by complete absence or extremely low levels of plasma and platelet fibrinogen. Note=The majority of cases of afibrinogenemia are due to truncating mutations. Variations in position Arg-35 (the site of cleavage of fibrinopeptide a by thrombin) leads to alpha-dysfibrinogenemias.
      Defects in FGA are a cause of amyloidosis type 8 (AMYL8) [MIM:105200]; also known as systemic non-neuropathic amyloidosis or Ostertag-type amyloidosis. AMYL8 is a hereditary generalized amyloidosis due to deposition of apolipoprotein A1, fibrinogen and lysozyme amyloids. Viscera are particularly affected. There is no involvement of the nervous system. Clinical features include renal amyloidosis resulting in nephrotic syndrome, arterial hypertension, hepatosplenomegaly, cholestasis, petechial skin rash.
    • Sequence similarities

      Contains 1 fibrinogen C-terminal domain.
    • Domain

      A long coiled coil structure formed by 3 polypeptide chains connects the central nodule to the C-terminal domains (distal nodules). The long C-terminal ends of the alpha chains fold back, contributing a fourth strand to the coiled coil structure.
    • Post-translational

      The alpha chain is not glycosylated.
      Forms F13A-mediated cross-links between a glutamine and the epsilon-amino group of a lysine residue, forming fibronectin-fibrinogen heteropolymers.
      About one-third of the alpha chains in the molecules in blood were found to be phosphorylated.
      Conversion of fibrinogen to fibrin is triggered by thrombin, which cleaves fibrinopeptides A and B from alpha and beta chains, and thus exposes the N-terminal polymerization sites responsible for the formation of the soft clot. The soft clot is converted into the hard clot by factor XIIIA which catalyzes the epsilon-(gamma-glutamyl)lysine cross-linking between gamma chains (stronger) and between alpha chains (weaker) of different monomers.
      Phosphorylation sites are present in the extracelllular medium.
    • Cellular localization

    • Information by UniProt
    • Database links

    • Alternative names

      • Ac1873 antibody
      • Fba5e antibody
      • FGA antibody
      • Fib antibody
      • Fib2 antibody
      • FIBA_HUMAN antibody
      • Fibrinogen alpha chain antibody
      • Fibrinogen, A alpha polypeptide antibody
      • Fibrinogen--alpha polypeptide chain antibody
      • Fibrinopeptide A antibody
      see all


    • Anti-Fibrinogen alpha chain antibody [EPR2918] (ab108616) at 0.9 µg/ml (purified) + Human plasma lysates at 15 µg

      Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 dilution

      Predicted band size: 95 kDa

      Blocking and diluting buffer: 5% NFDM/TBST
    • All lanes : Anti-Fibrinogen alpha chain antibody [EPR2918] (ab108616) at 1/2000 dilution (Unpurified)

      Lane 1 : Human plasma lysates
      Lane 2 : Human fetal liver lysates

      Lysates/proteins at 10 µg per lane.

      All lanes : HRP labelled goat anti-rabbit at 1/2000 dilution

      Predicted band size: 95 kDa


    ab108616 has not yet been referenced specifically in any publications.

    Customer reviews and Q&As


    Thank you for your inquiry.

    I heard back from the supplying lab that the peptide maps approximately between amino acids 695 - 715 of human fibrinogen (alpha chain) (UniProt: P02671).

    The predicted MW of the alpha chain is ˜91 kDa based on the fact that it is 831 a.a. long.[36-866]

    I hope this information helps. Please contact us with any other questions.

    Read More

    For licensing inquiries, please contact

    Sign up